AUA Expert Exchange Podcast: Discussion in GU Cancer (2022)

To further address the educational gaps identified in the AUA oncology educational needs assessments, the AUA has developed eight new episodes for the AUAUniversity podcast. The 2022 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this series will focus on the following topic-specific podcasts:

  1. Application of Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline in Clinical Practice
  2. Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer
  3. Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer
  4. PARP Inhibitors in Advanced Prostate Cancer Care
  5. Urothelial Carcinoma: Advances in Immuno-Oncology
  6. Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies
  7. Novel Imaging for Genitourinary Cancers
  8. Addressing Disparities and Variations in Care in GU Oncology

 

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from: 

Astellas 
AstraZeneca 
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc. 
Sanofi Genzyme 

Target Audience

  • Urologists

Learning Objectives

At the conclusion of these activities, participants will be able to:

Application of Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline in Clinical Practice

  1. Interpret the evidence and outcomes on the treatment of M0 HSPC, M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced Prostate Cancer Guideline encompassing metastatic HSPC and CRPC disease.
  2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.

Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer

  1. Assess how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer while avoiding unnecessary biopsies and detection of clinically unimportant cancers.
  2. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used.
  3. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
  4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy.

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer

  1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 
  2. Prioritize or stratify treatment options for metastatic prostate cancer.
  3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer.
  4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer.

PARP Inhibitors in Advanced Prostate Cancer Care

  1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.
  2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.
  3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.
  4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

Urothelial Carcinoma: Advances in Immuno-Oncology

  1. Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma.
  2. Prioritize treatment options in first line metastatic urothelial carcinoma.
  3. Evaluate second line options for metastatic urothelial carcinoma.

Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies

  1. Discuss the current targeted and immunotherapy options available for the treatment of RCC.
  2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
  3. Describe best practices in RCC patient selection for treatment options.
  4. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 

Novel Imaging for Genitourinary Cancers

  1. Review clinical trials and available PET imaging agents for the detection of prostate, kidney and urothelial cancer.
  2. Assess the indications, risks, and benefits of incorporating PET imaging to guide treatment of urologic cancer.

Addressing Disparities and Variations in Care in GU Oncology

  1. Discuss the impact of race and cultural barriers on optimal GU cancer care.
  2. Evaluate financial toxicity as a barrier to optimal patient care in urologic cancer.
  3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.
Course summary
Course opens: 
10/26/2022
Course expires: 
12/31/2023
Rating: 
0

EDUCATION COUNCIL DISCLOSURES

PDF icon Education Council Disclosures_2022.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Work Group Disclosures_2022.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

 

Faculty disclosures are located on individual activities. To view faculty disclosures, navigate to the "Take Course/Register" tab and select the activity you wish to view. 

 

 

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 4.0 hours

Release Date: October, 2022
Expiration Date: December, 2023

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
Please login or register to take this course.